MX2020004491A - Preparacion externa para tratar tinea unguium. - Google Patents

Preparacion externa para tratar tinea unguium.

Info

Publication number
MX2020004491A
MX2020004491A MX2020004491A MX2020004491A MX2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A MX 2020004491 A MX2020004491 A MX 2020004491A
Authority
MX
Mexico
Prior art keywords
preparation
properties
external preparation
efficacy
aspects
Prior art date
Application number
MX2020004491A
Other languages
English (en)
Spanish (es)
Inventor
Nobuyuki Natori
Hiroyuki Takabe
Takashi Ishimaru
Hiroshi Iseki
Keiichi Karasawa
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Publication of MX2020004491A publication Critical patent/MX2020004491A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2020004491A 2017-10-30 2018-10-29 Preparacion externa para tratar tinea unguium. MX2020004491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017209136 2017-10-30
PCT/JP2018/040047 WO2019088005A1 (ja) 2017-10-30 2018-10-29 爪白癬治療用の外用製剤

Publications (1)

Publication Number Publication Date
MX2020004491A true MX2020004491A (es) 2020-08-13

Family

ID=66333195

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004491A MX2020004491A (es) 2017-10-30 2018-10-29 Preparacion externa para tratar tinea unguium.

Country Status (14)

Country Link
US (1) US20210213002A1 (enExample)
EP (1) EP3705136A4 (enExample)
JP (2) JP6582158B1 (enExample)
KR (1) KR20200081432A (enExample)
CN (1) CN111295202B (enExample)
AU (1) AU2018358372A1 (enExample)
BR (1) BR112020008282A2 (enExample)
CA (1) CA3081163A1 (enExample)
IL (1) IL274100B2 (enExample)
MX (1) MX2020004491A (enExample)
RU (1) RU2020117569A (enExample)
SG (1) SG11202003820VA (enExample)
TW (1) TWI789448B (enExample)
WO (1) WO2019088005A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021132348A1 (ja) 2019-12-24 2021-07-01 科研製薬株式会社 エフィナコナゾールを含有する医薬
KR102217617B1 (ko) * 2020-08-14 2021-02-19 비엘엔에이치 주식회사 백선의 예방 또는 치료용 약학적 조성물
JP2022547755A (ja) * 2020-08-14 2022-11-16 ビーエルアンドエイチ カンパニー,リミテッド 白癬を防止又は処置するための医薬組成物
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
AU2023271525A1 (en) 2022-05-16 2024-12-05 Maruho Co., Ltd. Composition for treating ringworm
CN121772922A (zh) * 2023-08-02 2026-03-31 石原产业株式会社 甲癣用外用剂
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
JPS58162514A (ja) * 1982-03-19 1983-09-27 Sumitomo Chem Co Ltd 外用ゲル製剤
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
JP3688293B2 (ja) * 1993-09-29 2005-08-24 アルザ・コーポレーション モノグリセリド/乳酸エステル透過促進剤
JP5170486B2 (ja) * 1998-09-10 2013-03-27 バイオイコール ア−ゲー 局所適用性産物
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
JP5061519B2 (ja) 2006-07-12 2012-10-31 大正製薬株式会社 抗真菌剤含有o/wエマルション組成物
PL2191825T3 (pl) 2007-08-27 2016-11-30 Środek przeciwko grzybiczemu zapaleniu skóry
NL2003711C2 (en) * 2009-10-27 2011-04-28 Shield Mark B V Aqueous composition for topical application, method of preparation, uses and device.
NL2003786C2 (en) * 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
KR101463707B1 (ko) 2011-01-30 2014-11-19 메이지 세이카 파루마 가부시키가이샤 외용 항진균제
PH12014501000A1 (en) * 2011-11-04 2014-06-09 Agile Therapeutics Inc Dermal delivery compositions and methods
RU2621615C2 (ru) * 2012-09-14 2017-06-06 Пола Фарма Инк. Фармацевтическая композиция, содержащая луликоназол
RU2694758C2 (ru) * 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
TW201438742A (zh) * 2012-12-28 2014-10-16 大正製藥股份有限公司 皮膚適用製劑
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
JP6611014B2 (ja) * 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
SG11201801856XA (en) * 2015-09-18 2018-04-27 Kaken Pharmaceutical Co Ltd Biaryl derivative and medicine containing same
JP2017209136A (ja) 2016-05-23 2017-11-30 澁谷工業株式会社 電子線殺菌装置

Also Published As

Publication number Publication date
RU2020117569A3 (enExample) 2021-12-01
CN111295202A (zh) 2020-06-16
JP2020011967A (ja) 2020-01-23
JP6582158B1 (ja) 2019-09-25
CA3081163A1 (en) 2019-05-09
TW201922247A (zh) 2019-06-16
JPWO2019088005A1 (ja) 2019-11-14
RU2020117569A (ru) 2021-12-01
IL274100A (en) 2020-06-30
CN111295202B (zh) 2022-07-08
EP3705136A4 (en) 2021-08-18
IL274100B2 (en) 2023-06-01
WO2019088005A1 (ja) 2019-05-09
BR112020008282A2 (pt) 2020-10-20
SG11202003820VA (en) 2020-05-28
TWI789448B (zh) 2023-01-11
KR20200081432A (ko) 2020-07-07
EP3705136A1 (en) 2020-09-09
AU2018358372A1 (en) 2020-05-28
US20210213002A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
MX2020004491A (es) Preparacion externa para tratar tinea unguium.
CO2019008487A2 (es) Compuesto de quinazolina
UY38160A (es) Partículas implantables y métodos relacionados
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
EP4234633A3 (en) Wood preservative composition
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
ECSP13013035A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida
MX389697B (es) Nuevos derivados de pirazolopirimidina.
EA202092586A1 (ru) Ингибиторы magl
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
EA201991073A1 (ru) Ингибиторы magl
EA201991074A1 (ru) Ингибиторы magl
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
BR112019024566A2 (pt) inibidores de pirazol magl
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2018002015A (es) Composicion de absorcion percutanea.
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
UY36432A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio) carboxamida y compuesto(s) fungicida(s)
CR20170267A (es) Combinaciones de compuestos activos
UY37306A (es) Combinaciones de compuestos activos
EP3586848A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A COMPOUND SUITABLE TO CROSS THE HEMATOENCEPHALIC BARRIER AS AN ACTIVE PRINCIPLE TO PREVENT OR TREAT BRAIN CANCER
CR20170269A (es) Combinaciones de compuestos activos
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.